Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Lytix Biopharma AS ( (DE:6BG) ) is now available.
Lytix Biopharma AS announced that it will release its fourth-quarter and second-half 2025 financial results on February 12, 2025, accompanied by a live webcast presentation in English led by its CEO and CFO. The event, which will include a Q&A session and be followed by an online recording, is positioned to update investors and other stakeholders on the company’s financial performance and strategic progress as it advances its clinical-stage oncology pipeline.
More about Lytix Biopharma AS
Lytix Biopharma AS is an Oslo-based clinical-stage biotechnology company focused on developing a differentiated oncolytic molecule platform derived from host-defense peptides. Its lead candidate, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule aimed at inducing durable anti-cancer immunity, and the company is advancing a broader pipeline across multiple cancer indications and treatment settings, both as monotherapy and in combination regimens. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.
Average Trading Volume: 87,747
Current Market Cap: NOK713.3M
For detailed information about 6BG stock, go to TipRanks’ Stock Analysis page.